This site is intended for healthcare professionals
News

Dupixent approved by European Commission for children aged 6 to 11 years with severe asthma

Read time: 1 mins
Published:8th Apr 2022

Dupixent approved by European Commission for children aged 6 to 11 years with severe asthma with type 2 inflammation -Regeneron+ Sanofi

Regeneron Pharmaceuticals, Inc. and Sanofi announced that the European Commission (EC) has expanded the marketing authorization for Dupixent (dupilumab) in the European Union.

Dupixent is now also approved in children aged 6 to 11 years as an add-on maintenance treatment for severe asthma with type 2 inflammation characterized by raised blood eosinophils and/or raised fractional exhaled nitric oxide (FeNO), who are inadequately controlled with medium to high dose inhaled corticosteroids (ICS) plus another medicinal product for maintenance treatment.

Condition: Asthma
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Related news and insights